Anagrelide treatment in early pregnancy in a patient with JAK2V617F-positive essential thrombocythemia: case report and literature review

Sobas, Marta Anna; Pérez Encinas, Manuel Mateo; Rabuñal Martínez, María; Quinteiro García, Celsa; Bello López, José Luis
Thumbnail
Estadísticas
Estadísticas
Identificadores
Identificadores
URI: http://hdl.handle.net/20.500.11940/22721
PMID: 19887779
ESSN: 1421-9662
Registro completo
Servicios
Servicios
RISMendeleyLinksolver
Visualización o descarga de ficheros
Visualización o descarga de ficheros
Fecha de publicación
2009
Título de revista
Acta Haematologica
Tipo de contenido
Artigo
DeCS
resultado del embarazo | complicaciones hematológicas del embarazo | embarazo | quinazolinas | trombocitemia esencial | recién nacido
MeSH
Pregnancy | Quinazolines | Infant, Newborn | Thrombocythemia, Essential | Female | Pregnancy Complications, Hematologic | Women | Pregnancy Outcome
CIE
Trombocitemia idiopática (D47.3)
Resumen
[EN] Essential thrombocythemia (ET) has 2 peaks of incidence: one is at 60 years of age, the other at 30 years. In women, the peak at the earlier age presents challenges for management in Nevertheless, HDU and ANA are not recommended during pregnancy because of embryo/ fetotoxic effects observed in animals . There are scarce clinical data on adverse incidents when ANA is used during pregnancy in humans. We present a successful outcome of a 32-year-old woman with ET who was treated with ANA before becoming pregnant and during early pregnancy.